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Epigenetic modiﬁcationS-adenosylmethionine synthesis is a key process for cell function, and needs to be regulated at mul-
tiple levels. In recent years, advances in the knowledge of methionine adenosyltransferases have
been signiﬁcant. The discovery of nuclear localization of these enzymes suggests their transport
to provide the methyl donor, S-adenosylmethionine, for DNA and histone methyltransferases in epi-
genetic modiﬁcations, opening new regulatory possibilities. Previous hypotheses considered only
the cytoplasmic regulation of these enzymes, hence the need of an update to integrate recent ﬁnd-
ings. Here, we focus mainly on the liver and redox mechanisms, and their putative effects on local-
ization and interactions of methionine adenosyltransferases.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cells use methylation reactions to synthesize a large variety of
compounds, including neurotransmitters and phospholipids, but
also to regulate important functions such as gene expression [1–
3]. For this purpose, a methyl donor is needed, a role performed
mainly by S-adenosylmethionine (AdoMet). This metabolite is syn-
thesized frommethionine and ATP by methionine adenosyltransfe-
rases (MATs), which also hydrolyze the triphosphate chain of the
nucleotide to yield pyrophosphate and inorganic phosphate
(Fig. 1) [4]. Mammalian genomes contain three MAT genes that
code for two catalytic subunits, a1 (MAT1A) and a2 (MAT2A), and
a regulatory b-subunit (MAT2B). These subunits associate into
three isoenzymes that are homo- (MAT I and III) and hetero-oligo-
mers (MAT II) [2,5]. MAT I and MAT III are a tetramer and a dimer
of a1 subunits, respectively, whereas MAT II was recently postu-
lated to be a hetero-trimer of a2 and b-subunits in a 2:1 ratio
(Fig. 1) [6]. These isoenzymes show different afﬁnities for methio-
nine (S0.5Met), which are low for MAT III (1 mM), intermediate for
MAT I (100 lM) and high for MAT II (3.3–16 lM). Their Vmax followthe opposite trend compared to the S0.5Met, hence low AdoMet lev-
els correlate with MAT II expression and high levels of the methyl
donor with MAT I/III expression [2,3,5] (Fig. 1). Isoenzyme expres-
sion is tissue-dependent, that of MAT I/III being maximal in the li-
ver [7,8] whereas MAT II is the prevalent isoenzyme in
extrahepatic tissues [2]. Based on these kinetic and expression
data, the capacity to synthesize AdoMet is higher in the liver than
in other tissues and its levels are the highest followed closely by
those found in kidney [8]. In contrast, the hepatic methylation in-
dex (AdoMet/S-adenosylhomocysteine ratio) is lower than in other
tissues, a fact related to the number and importance of hepatic
transmethylation reactions, and the resulting S-adenosylhomocys-
teine production [1,8].
Classically, MATs were considered cytosolic proteins and MAT I/
III the hepatic isoenzymes; therefore, the previous hypothesis on
their regulation was focused on cytosolic MAT I/III activity and
association state [9], suggesting the need to explore post-transla-
tional modiﬁcations affecting these isoenzymes. This led to de-
tailed studies on the redox and phosphorylation mechanisms
acting on MAT I/III, which assumed that AdoMet synthesized in
the cytosol was transported to compartments such as the nucleus
for its use in methylation reactions (e.g., histone and DNA methyl-
ation). However, in 2009 our group demonstrated the nuclear
localization of MAT I [7], a report that was shortly followed by
Fig. 1. Metabolic links between redox stress and AdoMet synthesis. A schematic representation of the reactions linking AdoMet and glutathione synthesis (black dashed
lines) is shown, together with actions of glutathione, nitric oxide (NO) and NADP+ (green circles) levels on methionine adenosyltranferases. MATa1 subunits (aquamarine)
appear as homotetramers (MAT I) and homodimers (MAT III) that are inhibited by GSSG or NO (red dashed lines). MATa2 subunits (blue) appear as homodimers or
heterotrimers (MAT II) with the b-subunit (red). Reactions involved in NADP+ synthesis and the increased b/a2-dimer afﬁnity produced by cofactor binding (green dashed
lines) are shown.
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the nucleus [10,11]. These articles related nuclear localization of
MATs to enhanced histone methylation, therefore suggesting that
MATs are recruited to these locations where AdoMet synthesis is
needed, as pointed out in an editorial article accompanying Katoh’s
paper [12]. These data, together with the accumulated knowledge
on structure, post-translational modiﬁcations, and nuclear associa-
tion states, prompted us to update and expand the previous regu-
latory model, incorporating also data concerning MAT II.
2. Structural data on methionine adenosyltransferases
Crystal structures of several MAT homo-oligomers in free active
site conformations or complexed with substrates, products, or their
analogues are now available [5,13,14]. These structures also in-
cluded Mg2+ and K+ ions and NADP+. The three-domain organiza-
tion of a1-monomers is preserved in a2-subunits and, given the
high level of sequence conservation among catalytic subunits
[15], this organization is expected to be a common feature
throughout the MAT family. A large hydrophobic surface consti-
tutes the monomer–monomer interface, where the two dimer ac-
tive sites are opposed to one another. Both monomers contribute
residues to the active sites, and hence monomers are unable to
synthesize AdoMet. Access to the active site is controlled by a ﬂex-
ible loop that contains a cysteine residue in a1 [5,13]. The small
interface between dimers in the tetramer involves the central do-
main of the a-subunits, fewer interactions contributing to dimer
association in mammalian tetramers than in their Escherichia coli
counterpart [16].
The regulatory b-subunit shows no structural relationship with
a-subunits and has been classiﬁed as a member of the oxidoreduc-
tase PFAM 04321 family. As such, the b-subunit contains a FAD+/
NADP+ Rossman fold, where NADP+ has been crystallized. Binding
of the cofactor induces ordering into three regions (A–C) of thesubunit, two of them (A and B) directly involved in NADP+ binding
[6]. The MAT II hetero-oligomer interface is proposed to involve re-
gions A and C of the b-subunit, together with the central domain of
a2-subunits [6].
3. Methionine adenosyltransferases in pathology
Most studies on the pathophysiological role of MAT isoen-
zymes have been carried out in liver (recently reviewed in
[17]), where 50% of the ingested methionine is metabolized
[18]. However, alterations in expression of MAT isoenzymes and
AdoMet levels have been reported in a variety of pathologies that
include hepatocellular carcinoma (HCC), diabetes, and Alzheimer’s
or Wilson’s disease [2,3,19]. HCC studies showed changes in pro-
moter methylation of MAT1A (hypermethylated) and MAT2A
(hypomethylated), leading to an expression switch towards re-
duced MAT1A and increased MAT2A mRNA levels, that is fol-
lowed by enhanced MAT2B expression [17,20]. This expression
switch correlates with a reduction in hepatic AdoMet levels, as
expected from the exchange from high Vmax isoenzymes to low
Vmax MAT II [2,3,17,21] (Fig. 1). The link between HCC and Ado-
Met levels has been conﬁrmed using two knockout mouse models
that exhibited either low (MAT1A KO) or high (glycine N-methyl-
transferase, GNMT KO) hepatic AdoMet concentrations and that
spontaneously developed HCC [22,23]. This relationship has been
strengthened by knocking down microRNAs (miR-664, miR-485-
3p, miR-495) that are highly expressed in HCC and reduce MAT1A
expression [24]. A large amount of work has been devoted to elu-
cidating the signaling cascades relating changes in AdoMet syn-
thesis and disease (reviewed in [17]). Among them are those
involving NFjB and AP-1, for which MAT2A and MAT2B promoters
include binding sites and that also induce iNOS expression, thus
enhancing nitric oxide (NO) production leading to MAT I/III inhi-
bition (see below).
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and only in a few individuals demyelination has been reported
[25]. These neurological symptoms were described for patients
with alterations in the C-terminal end of the a1-subunit, but only
in one case was exogenous AdoMet used to obtain an improvement
in myelination [25,26]. Importantly, a mutant form with an alter-
ation at the C-terminal end, analogous to those causing human
demyelination, showed nuclear accumulation in living cells [7].
The process by which demyelination occurs is unknown, although
an anomalous a1/a2 oligomerization was postulated to reduce
AdoMet synthesis [27]. The availability of the structures for MAT
subunits, data showing expression of MAT1A in extrahepatic tis-
sues, and the demonstration that MATa1 localizes mainly to the
nucleus in most cell types except hepatocytes, allowed reexamina-
tion of this hetero-oligomerization hypothesis in 2011 [28].
4. Methionine adenosyltransferases and redox stress
Several disease models, including treatments with carbon tetra-
chloride [29] or lipopolysaccharide [30], buthionine sulfoximine
intoxication [31], and Long Evans Cinnamon rats (LEC; Wilson’s
disease model) [19], have shown a relationship between redox
stress and MAT function. In these models reductions in glutathione
synthesis, alterations in expression of MAT genes, lower levels of
MATa1 and/or inhibition of MAT I/III activity were observed. Re-
sults derived from these studies, together with in vitro experi-
ments carried out in parallel, demonstrated MAT I/III inhibition
by GSSG and modulation of this activity by the GSH/GSSG ratio
[32,33]. Redox stress also altered the association state of MAT I/
III, leading to either the accumulation of inactive dimers or even
monomers [32,34]. Moreover, C121, the cysteine located at the ac-
tive site loop of MAT I/III, was modiﬁed by NO and hydroxyl radi-
cals in some of these in vivo models, leading to enzyme
inactivation [35–37]. Therefore C121 nitrosylation was proposed
to force the loop into a position that blocks substrate admission
into the catalytic site, thus precluding AdoMet synthesis.
The key role of cysteine residues in activity and oligomerization
of MAT I/III was also demonstrated using chemical modiﬁcation or
mutagenesis [38–40]. The C69S mutant accumulated as a1-dimers
and elimination of cysteines between positions 35–105 altered
MAT I/III ratios [40]. However, none of these individual mutations
fully inactivates MAT I/III [16,40]. Additionally, in vitro production
of the C35-C61 intrasubunit disulﬁde bond blocked dimer-tetra-
mer interconversion, without affecting activity [16]. This disulﬁde
in the central domain was a normal feature of the puriﬁed hepatic
a1-oligomers [41], and the conformational changes it induced
were observed as subtle changes in SDS–PAGE mobility of MATa1
upon thiopropyl Sepharose puriﬁcation [32].
Hepatic copper accumulation in LEC rats induces redox stress,
the MAT1A to MAT2A expression switch, inhibition of MAT I/III
activity, and decreased AdoMet levels [19]. In contrast, MAT2B
expression is almost suppressed. The consequence is that MAT II
oligomers in these livers must be mainly composed by a2-subunits
with higher S0.5Met than MAT II hetero-oligomers [2]. Moreover,
copper altered folding of a1 and a2-subunits in the test tube, sug-
gesting a potential folding problem in vivo. The lack of cysteines
equivalent to C121 and C61 in the MATa2 sequence precludes inhi-
bition by NO or intrasubunit disulﬁde production [5,15], and no re-
ports have shown whether MATa2 activity can be modulated by
GSH/GSSG ratios. Therefore, a redox regulatory mechanism similar
to that described for MAT I/III seemed unlikely for MAT II. Our re-
cent report demonstrating increased afﬁnity of NADP+-bound b-
subunit for a2-dimers [6], suggests that high levels of this cofactor
(e.g., during drug detoxiﬁcation) would favor production of MAT II.
These data open the possibility that redox regulation is exerted ondifferent subunits and with opposite results for AdoMet production
in each type of MAT isoenzyme.
5. Proposed hypothesis
All the data summarized in the previous sections suggest a re-
dox regulatory mechanism controlling mammalian MAT isoen-
zymes in a concerted way (Fig. 2). This redox mechanism directs
AdoMet production at several levels including MAT expression,
activity, oligomerization, and potentially subcellular localization.
Only some of the models studied to date showed MAT expression
changes induced by oxidative stress (reviewed in [2,17]). Lack of
consensus sequences for metal (MREs) or antioxidant (AREs) re-
sponse elements in the corresponding promoters precludes direct
effects through binding of transcription factors to such elements,
as previously discussed [19]. Other options include promoter bind-
ing of redox stress-regulated transcription factors (e.g., NFjB in
MAT2B and MAT2A)[2,42], changes in promoter methylation status
directly or indirectly involving redox regulation of demethylases or
methyltransferases [43,44], or changes in other epigenetic modiﬁ-
cations controlled by redox stress (e.g., sirtuin binding of NAD+)
(Fig. 2A). Additionally, MAT1A and MAT2A mRNAs can be regu-
lated by 30-UTR binding of AUF1 or meHuR/HuR, respectively
[45], an AdoMet-dependent process that could be modulated by re-
dox mechanisms.
Under diverse redox conditions distinct subunit associations
can be produced that may differ among subcellular compartments.
Thus, fully reduced recombinant subunits appear in a tetramer/di-
mer concentration-dependent equilibrium [46,47] (Fig. 2B; step 1).
However, in liver cytosol MATa1 homo-oligomers are stable, a fact
ascribed to the presence of the C35-C61 intrasubunit disulﬁde
(step 2) [16,41,46]. Under redox stress the GSH/GSSG ratio is re-
duced (<50) and different oxidation degrees could be produced
favoring dissociation into dimers (step 4; observed in cirrhotic liv-
ers) or even into inactive a1-monomers (step 5) [32]. Moreover,
in vivo C121 nitrosylation can be the initial oxidation event, fol-
lowed by the GSSG effects (steps 4 and 5). Altogether these
changes result in reduction of cytosolic MAT I/III activity during re-
dox stress, and hence of AdoMet levels available for methylation.
Confocal microscopy demonstrated the presence of nuclear
MATa1-EGFP in living cells [7], but the mechanisms that govern
its subcellular localization are unknown. Among the possibilities,
protein–protein interactions may induce direct or indirect binding
of the homo-oligomer to importins or exportins (step 6), a step that
might be favored by the presence of post-translational modiﬁca-
tions on MATa1. Redox stress is a putative mechanism controlling
subcellular localization, but there is no available information con-
cerning the redox state of the nuclear MATa1 forms. Therefore, our
proposal includes transport of fully reduced or partially oxidized
MATa1 oligomers through the nuclear pore (step 6), and oxida-
tion/reduction of these species if nuclear GSH/GSSG ratios change
(step 7). Given that MAT activity is detected in nuclear fractions
[7], nuclear MAT I species must be active to synthesize AdoMet,
and nuclear monomers may arise from tetramer dissociation (step
8). Again, the reduced/oxidized character of these monomers is un-
known, but they may associate into MAT I when higher nuclear
levels of AdoMet are needed for epigenetic remodeling. Truncation
of the C-terminal end of MATa1 induced nuclear accumulation [7];
hence, modiﬁcations in residues in this area of the molecule, such
as T342 phosphorylation [48] or others that have been detected by
proteomic approaches (PhosphoSite Plus), may play a role in sub-
cellular localization.
Several cell culture experiments and MATa2 and b puriﬁcation
from mammalian tissues demonstrated the existence of MAT II
hetero-oligomers (Fig. 2C) [6]. In bacterial cytosol, a reduced
Fig. 2. Scheme of redox regulation. Experimental changes affecting MATs are shown (thick arrows), together with putative additional points of redox-regulation (dotted
arrows). Effects on transcription (A), including promoter methylation and putative binding of redox-regulated transcription factors, are depicted together with factors
affecting mRNA stability. Thick lines denote results concerning MAT I/III (B) or MAT II (C) proteins in animal models and living cells (green) or in vitro (black), and putative
reactions appear as dotted lines. Fully reduced MATa1 (aquamarine) and MATa2 (blue), appear in a concentration-dependent equilibrium between tetramers and dimers (1).
Partially oxidized MATa1 (orange), containing the C35–C61 intrasubunit disulﬁde (C–C), associate into stable oligomers (2–3). NO and GSSG inhibition (4) and full oxidation
and dissociation (5) are also depicted. Putative redox-regulated steps of MAT transport through the nuclear pore complex (NPC) and nuclear function are indicated,
considering also putative interactions with unidentiﬁed X-proteins (6–8). Free b-subunits (red) appear as monomers and dimers (9) to which NADP+ (green circles) binds (10),
and which can associate with a2-dimers into heterotrimers (11–12). Putative redox-regulated steps for MAT II transport and function in the nucleus, including association
with MafK transcription factor, are indicated (13–14).
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dependent associations, dimers and tetramers for a2 (step 1) and
monomers and dimers for b-subunits (step 9) [6]. In vitro, b-mono-
mers can bind NADP+ (step 10), but both free- and NADP+-bound
subunits associate into stable MAT II hetero-trimers (steps 11
and 12). NO production, drug detoxiﬁcation and GSSG reductionenhance NADP+ levels (Fig. 1). Under these conditions the afﬁnity
of NADP+-b for a2-dimers is increased (steps 10 and 12), and
MAT II association (with the lower Vmax) is favored leading to re-
duced AdoMet levels in the cytosol. However, not all the splicing
forms of the b-subunit can bind NADP+, thus providing selectivity
to this regulation mechanism [6,42].
M.A. Pajares et al. / FEBS Letters 587 (2013) 1711–1716 1715Indirect immunoﬂuorescence detected nuclear MAT II, where
a2-subunits interact with the MafK transcription factor, acting as
corepressors [10]. The mechanisms of nucleocytoplasmic transport
of MAT II remain also unknown, although again protein–protein
interactions or post-translational modiﬁcations might be involved
(step 13). These putative modiﬁcations may result from oxidative
stress, a point that deserves investigation. Moreover, NADP+ bind-
ing may favor one or another subcellular localization (step 13), the
cofactor being lost once the adequate compartment is reached
(step 14). Additional modiﬁcations in a2 and b-subunits that
may have a role in localization include those identiﬁed by mass
spectrometry (PhosphoSite Plus) [49–51]. Despite the similarity
among C-terminal ends of MATa1 and MATa2, the small differ-
ences detected may allow differential regulation of their subcellu-
lar localization [7].
All these association changes render species differing in their
Vmax, and hence in AdoMet production. When liver function is nor-
mal the high Vmax MAT isoenzymes are prevalent, synthesizing en-
ough AdoMet to meet cell requirements. However, when hepatic
function is challenged, the defense or drug detoxiﬁcation mecha-
nisms induce production of NO, GSSG and/or increased NADP+ lev-
els (Fig. 1). All these metabolic changes led to inhibition of the
normal hepatic isoenzymes (MAT I/III) and increased levels of
MAT II, the net result being a reduction of the AdoMet levels avail-
able for methylation reactions (e.g., DNA hypomethylation). These
concerted actions guarantee AdoMet synthesis in the cytosol under
a minimum supply of methionine, but whether the same effects
can be extrapolated to nuclear behavior should be explored.
In summary, redox stress data suggest a fundamental role for
this mechanism in AdoMet homeostasis. Negative effects on MAT
I/III would be exerted at different levels from expression to activity
of the a1-subunit, whereas compensatory/positive effects on MAT
II would occur through the regulatory b-subunit. The putative role
of these mechanisms in governing subcellular localization of MATs
and the relationship between changes in localization and pathol-
ogy remain unexplored.
Acknowledgments
The authors wish to thank N. Mantei for his suggestions. This
work was supported by Grants of the Ministerio de Economía y
Competitividad (BFU2008-00666 and BFU2009-08977 to M.A.P.,
and SAF2009-11642 and SAF2012-36519 to D.P.S.) and Instituto
de Salud Carlos III (RETICS RD12/0013/0008 to D.P.S. and FIS
PI12/01196 to L.A.).
References
[1] Cantoni, G.L. (1975) Biological methylation: selected aspects. Annu. Rev.
Biochem. 44, 435–451.
[2] Pajares, M.A. and Markham, G.D. (2011) Methionine adenosyltransferase (S-
adenosylmethionine synthetase). Adv. Enzymol. Relat. Areas Mol. Biol. 78,
449–452.
[3] Mato, J.M. et al. (1997) S-adenosylmethionine synthesis: molecular
mechanisms and clinical implications. Pharmacol. Ther. 73, 265–280.
[4] Cantoni, G.L. (1951) Activation of methionine for transmethylation. J. Biol.
Chem. 189, 745–754.
[5] Markham, G.D. and Pajares, M.A. (2009) Structure–function relationships in
methionine adenosyltransferases. Cell. Mol. Life Sci. 66, 636–648.
[6] Gonzalez, B. et al. (2012) NADP(+) binding to the regulatory subunit of
methionine adenosyltransferase II increases intersubunit binding afﬁnity in
the hetero-trimer. PLoS ONE 7, e50329.
[7] Reytor, E. et al. (2009) Conformational signals in the C-terminal domain of
methionine adenosyltransferase I/III determine its nucleocytoplasmic
distribution. FASEB J. 23, 3347–3360.
[8] Chen, N.C. et al. (2010) Regulation of homocysteine metabolism and
methylation in human and mouse tissues. FASEB J. 24, 2804–2817.
[9] Pajares, M.A. et al. (1992) How is rat liver S-adenosylmethionine synthetase
regulated? FEBS Lett. 309, 1–4.
[10] Katoh, Y. et al. (2011) Methionine adenosyltransferase II serves as a
transcriptional corepressor of Maf oncoprotein. Mol. Cell 41, 554–566.[11] Xia, M. et al. (2010) Novel function and intracellular localization of
methionine adenosyltransferase 2{beta} splicing variants. J. Biol. Chem. 285,
20015–20021.
[12] Gibson, B.A. and Kraus, W.L. (2011) Small molecules, big effects: a role for
chromatin-localized metabolite biosynthesis in gene regulation. Mol. Cell 41,
497–499.
[13] Gonzalez, B. et al. (2000) The crystal structure of tetrameric methionine
adenosyltransferase from rat liver reveals the methionine-binding site. J. Mol.
Biol. 300, 363–375.
[14] Gonzalez, B. et al. (2003) Crystal structures of methionine adenosyltransferase
complexed with substrates and products reveal the methionine-ATP
recognition and give insights into the catalytic mechanism. J. Mol. Biol. 331,
407–416.
[15] Sanchez-Perez, G.F. et al. (2004) Methionine adenosyltransferase as a useful
molecular systematics tool revealed by phylogenetic and structural analyses. J.
Mol. Biol. 335, 693–706.
[16] Sanchez-Perez, G.F. et al. (2003) Role of an intrasubunit disulﬁde in the
association state of the cytosolic homo-oligomer methionine
adenosyltransferase. J. Biol. Chem. 278, 7285–7293.
[17] Lu, S.C. and Mato, J.M. (2012) S-adenosylmethionine in liver health, injury, and
cancer. Physiol. Rev. 92, 1515–1542.
[18] Zeisel, S.H. and Wurtman, R.J. (1979) Dietary intake of methionine: inﬂuence
of brain S-adenosylmethionine in: Transmethylation (Usdin, E., Borchardt, R.T.
and Creveling, C.R., Eds.), pp. 59–68, Elsevier, New York.
[19] Delgado, M. et al. (2008) Early effects of copper accumulation on methionine
metabolism. Cell. Mol. Life Sci. 65, 2080–2090.
[20] Torres, L. et al. (2000) Liver-speciﬁc methionine adenosyltransferase MAT1A
gene expression is associated with a speciﬁc pattern of promoter methylation
and histone acetylation: implications for MAT1A silencing during
transformation. FASEB J. 14, 95–102.
[21] Cai, J. et al. (1996) Changes in S-adenosylmethionine synthetase in human
liver cancer: molecular characterization and signiﬁcance. Hepatology 24,
1090–1097.
[22] Lu, S.C. et al. (2001) Methionine adenosyltransferase 1A knockout mice are
predisposed to liver injury and exhibit increased expression of genes involved
in proliferation. Proc. Natl. Acad. Sci. 98, 5560–5565.
[23] Martinez-Chantar, M.L. et al. (2008) Loss of the glycine N-methyltransferase
gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 47,
1191–1199.
[24] Yang, H. et al. (2013) MicroRNAs regulate methionine adenosyltransferase 1A
expression in hepatocellular carcinoma. J. Clin. Invest. 123, 285–298.
[25] Mudd, S.H. (2011) Hypermethioninemias of genetic and non-genetic origin: a
review. Am. J. Med. Genet. C: Semin. Med. Genet. 157, 3–32.
[26] Chamberlin, M.E. et al. (2000) Methionine adenosyltransferase I/III deﬁciency:
novel mutations and clinical variations. Am. J. Hum. Genet. 66, 347–355.
[27] Hazelwood, S. et al. (1998) Normal brain myelination in a patient homozygous
for a mutation that encodes a severely truncated methionine
adenosyltransferase I/III. Am. J. Med. Genet. 75, 395–400.
[28] Pajares, M.A. and Pérez, C. (2011) The relationship between human MAT1A
mutations and disease: a folding and association problem? in: Protein Folding
(Walters, EC., Ed.), pp. 261–287, Nova Science Publishers, New York.
[29] Corrales, F. et al. (1992) S-adenosylmethionine treatment prevents carbon
tetrachloride-induced S-adenosylmethionine synthetase inactivation and
attenuates liver injury. Hepatology 16, 1022–1027.
[30] Avila, M.A. et al. (1997) Regulation of rat liver S-adenosylmethionine
synthetase during septic shock: role of nitric oxide. Hepatology 25, 391–396.
[31] Corrales, F. et al. (1991) Inhibition of glutathione synthesis in the liver leads to
S-adenosyl-L-methionine synthetase reduction. Hepatology 14, 528–533.
[32] Pajares, M.A. et al. (1992) Modulation of rat liver S-adenosylmethionine
synthetase activity by glutathione. J. Biol. Chem. 267, 17598–17605.
[33] Martinez-Chantar, M.L. and Pajares, M.A. (1996) Role of thioltransferases on
the modulation of rat liver S-adenosylmethionine synthetase activity by
glutathione. FEBS Lett. 397, 293–297.
[34] Cabrero, C. et al. (1988) Speciﬁc loss of the high-molecular-weight form of S-
adenosyl-L-methionine synthetase in human liver cirrhosis. Hepatology 8,
1530–1534.
[35] Avila, M.A. et al. (1998) Speciﬁc interaction of methionine adenosyltransferase
with free radicals. BioFactors 8, 27–32.
[36] Sanchez-Gongora, E. et al. (1997) Interaction of liver methionine
adenosyltransferase with hydroxyl radical. FASEB J. 11, 1013–1019.
[37] Ruiz, F. et al. (1998) Nitric oxide inactivates rat hepatic methionine
adenosyltransferase in vivo by S-nitrosylation. Hepatology 28, 1051–1057.
[38] Pajares, M.A. et al. (1991) The role of cysteine-150 in the structure and activity
of rat liver S-adenosyl-L-methionine synthetase. Biochem. J. 274, 225–229.
[39] Corrales, F. et al. (1990) Inactivation and dissociation of S-adenosylmethionine
synthetase by modiﬁcation of sulfhydryl groups and its possible occurrence in
cirrhosis. Hepatology 11, 216–222.
[40] Mingorance, J. et al. (1996) Site-directed mutagenesis of rat liver S-
adenosylmethionine synthetase. Identiﬁcation of a cysteine residue critical
for the oligomeric state. Biochem. J. 315, 761–766.
[41] Martinez-Chantar, M.L. and Pajares, M.A. (2000) Assignment of a single
disulﬁde bridge in rat liver methionine adenosyltransferase. Eur. J. Biochem.
267, 132–137.
[42] Yang, H. et al. (2008) Expression pattern, regulation, and functions of
methionine adenosyltransferase 2beta splicing variants in hepatoma cells.
Gastroenterology 134, 281–291.
1716 M.A. Pajares et al. / FEBS Letters 587 (2013) 1711–1716[43] Chen, C.C. et al. (2012) The mammalian de novo DNA methyltransferases
DNMT3A and DNMT3B are also DNA 5-hydroxymethylcytosine
dehydroxymethylases. J. Biol. Chem. 287, 33116–33121.
[44] Zawia, N.H. et al. (2009) Epigenetics, oxidative stress, and Alzheimer disease.
Free Radic. Biol. Med. 46, 1241–1249.
[45] Vazquez-Chantada, M. et al. (2010) HuR/methyl-HuR and AU-rich RNA
binding factor 1 regulate the methionine adenosyltransferase expressed
during liver proliferation, differentiation, and carcinogenesis.
Gastroenterology 138, 1943–1953.
[46] Mingorance, J. et al. (1997) Recombinant rat liver S-adenosyl-L-methionine
synthetase tetramers and dimers are in equilibrium. Int. J. Biochem. Cell Biol.
29, 485–491.[47] Lopez-Vara, M.C. et al. (2000) Refolding and characterization of rat liver
methionine adenosyltransferase from Escherichia coli inclusion bodies. Protein
Expr. Purif. 19, 219–226.
[48] Pajares, M.A. et al. (1994) Protein kinase C phosphorylation of rat liver S-
adenosylmethionine synthetase: dissociation and production of an active
monomer. Biochem. J. 303, 949–955.
[49] Choudhary, C. et al. (2009) Lysine acetylation targets protein complexes and
co-regulates major cellular functions. Science 325, 834–840.
[50] Kim, W. et al. (2011) Systematic and quantitative assessment of the ubiquitin-
modiﬁed proteome. Mol. Cell 44, 325–340.
[51] Moritz, A. et al. (2010) Akt-RSK-S6 kinase signaling networks activated by
oncogenic receptor tyrosine kinases. Sci. Signal. 3, ra64.
